18.3 C
Monday, July 15, 2024

Medidata Launches AI-driven Clinical Data Studio

Must read

Medidata launches Clinical Data Studio, an AI-powered platform for faster clinical trial data review and reconciliation. It integrates data from various sources for holistic insights.

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, announced the launch of Medidata Clinical Data Studio. This unified experience unlocks the true power of clinical research data. This groundbreaking technology gives stakeholders greater control over the quality of data and the ability to deliver safer trials to patients faster.

Built on the industry’s unified platform, Clinical Data Studio integrates data from Medidata and non-Medidata sources, accelerating decision-making across the full clinical trial process and delivering holistic data and risk strategies that connect patients, sites, and sponsors. Through AI, study teams can identify potential data issues and safety signals more effectively, resulting in a more accurate understanding of patients. This reduces the challenges posed by siloed data systems and enables action data review and reconciliation up to 80 percent faster.

“Clinical Data Studio unlocks the broad ecosystem of clinical data. Powered by embedded AI, we are democratizing access to data and revealing the signals, risks, and insights that matter most. Together, this accelerates trial execution and creates rich data for discoveries,” said Tom Doyle, chief technology officer at Medidata.

Clinical Data Studio offers a comprehensive data integration, transformation, and management workspace. It includes AI-assisted data reconciliation and anomaly detection, self-serve data listings, robust risk-based quality management, and tools to implement a holistic data and risk strategy supported by workflows and visualizations.

Also Read: Web Scraping for AI Training: Can it Comply with GDPR?

“As data volume and sources grow exponentially, managing this data and garnering real-time insights is becoming increasingly complex. Not only is this impacting time-to-market, but it is also delaying the timely delivery of therapies to patients, thus impacting patients’ lives,” said Dr. Nimita Limaye, research vice president of Life Sciences R&D Strategy and Technology, IDC. “By enabling users to manage all their data, both Medidata and non-Medidata data, in one place, Medidata Clinical Data Studio has the potential to disrupt the industry by accelerating clinical trials and getting therapies to patients faster.”

More articles

Latest posts